Search results
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic...
Digital Journal· 2 days agoHUNTINGTON BEACH, CA / ACCESSWIRE / April 29, 2024 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTC PINK:CPMV), a development-stage biotechnology company focused on the development ...
Soleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide Choline
Market Watch· 2 days agoBy Chris Wack Soleno Therapeutics were trading near a three-year high after the Food and Drug Administration granted breakthrough therapy designation for...
Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary...
WFRV 5 Green Bay· 6 days agoCBL-514 is under development for multiple indications, including Cellulite, Local Fat Reduction (currently in Phase 2b), and Durum's disease (currently in Phase 2), which brought Caliway the ...
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
Morningstar· 6 days agoCandel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight ...
Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2
WJTV Jackson· 10 hours agoEllipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today ...
CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using...
The Yuma Sun· 1 day agoDenovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the California Institute for Regenerative Medicine (CIRM ...
Genflow Biosciences PLC Announces Total Voting Rights
Digital Journal· 1 day ago...Poolbeg Pharma PLC Announces Appointment of Joint Broker Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate Trident Royalties PLC Announces Notice of Q1 2024 Activities Update Centamin PLC Announces Total Voting Rights...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 7 days agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in...
Digital Journal· 1 day ago...
Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment...
Morningstar· 6 days agoDALLAS, April 25, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical
